GMAB - Genmab AS logo

GMAB

Genmab AS

Compare GMAB Hold

Genmab A/S develops antibody-based therapies for cancer and other diseases, offering products like Epcoritamab for lymphomas and Tivdak for cervical cancer. It also markets DARZALEX for multiple myeloma and Kesimpta for multiple sclerosis.

⚕️ Healthcare NASDAQ Listed 2009 kr DKK
$1,000 invested 10 years ago →$2,055today

Score Overview

1 Year
Score
Net Growth-18.23%
Net TrendShrank
Net Income Consistency—
Rev Growth10.96%
Rev TrendGrew
Revenue Consistency—
5 Years
Score4.4
Net Growth-73.35%
Net Trend40%
Net Income Consistency—
Rev Growth-50.92%
Rev Trend80%
Revenue Consistency—
10 Years
Score
Net Growth-33.61%
Net Trend50%
Net Income Consistency
Rev Growth127.47%
Rev Trend80%
Revenue Consistency
All Time
Score
Net Growth177.97%
Net Trend65%
Net Income Consistency
Rev Growth7x
Rev Trend76%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Genmab AS has ranked, year by year

Measure
Fundamentals Window
1Y5Y10Y20Y30YAll time

Showing 5 years ranking history by HDB Score.

Reached the top 50 on HDB Score in 1 year, the longest run being 1 in a row — but not in 2021.

  • GMAB

2015: 45.0% · 2021: 3.5% · free through 2021 · longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-28
$ 35.36—
1 Year2025-09-26
$ 29.0721.64%
5 Years2021-09-28
$ 42.05-15.91%
10 Years2016-09-28
$ 17.21105.49%
All Time2009-06-01
$ 3.779x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026kr 4.13Bkr 788Mkr 1.50B
2025kr 3.72Bkr 963Mkr 1.71B
2024kr 21.52Bkr 7.84Bkr 21.10B
2023kr 16.47Bkr 4.35Bkr 28.13B
2022kr 14.50Bkr 5.45Bkr 22.32B
2021kr 8.41Bkr 2.95Bkr 19.33B
2020kr 10.11Bkr 4.75Bkr 16.07B
2019kr 5.36Bkr 2.16Bkr 10.97B
2018kr 3.02Bkr 1.47Bkr 6.10B
2017kr 2.36Bkr 1.10Bkr 5.42B
2016kr 1.81Bkr 1.18Bkr 3.92B
2015kr 1.13Bkr 763Mkr 3.49B
2014kr 850Mkr 301Mkr 2.66B
2013kr 663Mkr 112Mkr 1.55B
2012kr 484M-kr 487Mkr 1.50B
2011kr 350M-kr 596Mkr 1.10B
2010kr 582M-kr 321Mkr 1.64B
IPO2009kr 586M-kr 1.01Bkr 1.27B
GMAB - Genmab AS logo

Genmab AS fundamental performance

Between 2020 and 2025, revenue declined from kr 10.11B to kr 3.72B and net income declined from kr 4.75B to kr 963M. Revenue increased in 4 of those 5 years; net income in 2.

Across Genmab AS's full reported history, from 2009 to 2025, revenue grew from kr 586M to kr 3.72B and net income went from -kr 1.01B to kr 963M. Revenue increased in 76% of the years measured; net income in 65%.

Genmab AS currently holds a 5-year HDB Score of 4.4 out of 10. How the HDB Score is calculated.

Membership

Continue GMAB’s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,816 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies